Crescita Therapeutics Inc. TSX: CTX

Transcription

1 Crescita Therapeutics Inc. January 2018

2 Safe Harbour Certain information contained in these materials and to be discussed during this presentation constitute forwardlooking information within the meaning of applicable securities laws, including, among others, statements concerning the Company s objectives and strategies to achieve those objectives, sales of the Company s products, the Company s product candidates and the timeline for their development and commercialization, the Company s future financial condition and performance, potential acquisition and licensing transactions, as well as other statements with respect to management s beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Such forward-looking information reflect management s current beliefs as of the date hereof and are based on information currently available to Management. Although the forward-looking information contained in these materials and to be discussed during this presentation is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking information is based on the Company s estimates and assumptions, and is subject to risks and uncertainties, that could cause actual results to differ materially from such forward-looking information, including those described in the Company s annual information form, management discussion and analysis and other documents filed with Canadian securities regulators, copies of which are available under the Company s profile at Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. 2

3 Who We Are? Crescita Therapeutics is a fully integrated proudly Canadian Dermo-cosmetic company (CDN market size $2.0B*) We offer our clients superior quality consumer skincare products and currently have one FDA approved prescription product called Pliaglis We own multiple proprietary drug delivery platforms as well as other up and coming prescription products in our 3 pipeline: Flexicaine Phase III MiCal 1 - Phase II MiCal 2 Pre-Clinical * Source: IBIS World Industry Report July All amounts presented in Canadian dollars, unless otherwise noted. Clinical development funded by 3 rd parties

4 Well Positioned for Growth: Status of Prescription Products Pipeline Formulation Development/ Pre-Clinical IND Filed Phase 1 Phase 2 Phase 3 Commercial Pliaglis U.S. Rights Out-licensed to Taro (Crescita Rights - Canada, Mexico; Galderma - ROW) Flexicaine (2 nd generation Pliaglis Out-licensed to Taro) MiCal 1* (Topical treatment of Psoriasis) MiCal 2* ** Cosmetic Portfolio * MiCal 1 and MiCal 2 target development of two dermatological products for treatment of plaque psoriasis * Crescita responsible for formulation development/ip and providing MMPE technology * Fully funded by our partner Ferndale Laboratories and a leading U.S. CRO * Economic benefits to be shared upon out-licensing ** Cosmetic Portfolio internal development 4

5 Investment Consideration New company trading near cash value Significant Rx royalty/milestone revenue potential: Pliaglis launch in U.S.; and New Phase II products to be out-licensed Non-Rx business well positioned for domestic and international growth Projected profitability of non-rx business within 12 months Strong shareholder support for growth & acquisitions 5

6 Business Development Executing on the Business Development Pillar Through 4 Corporate Priorities Strategic Acquisitions &/or Out-licensing deals Developing CMO activities Further Developing International Markets Organic Growth of Existing Product Lines 6

7 Well Positioned for Growth: Innovation through Our Technologies & Expertise Topical and Transdermal Drug Delivery MMPE Multiplexed Molecular Penetration Enhancers Combinations of FDA approved excipients deliver actives into or through the skin Peel & DuraPeel Phase-Changing Topical Cream Phase-changing cream using selfocclusion to deliver actives into or through the skin In-house R&D Team Modern R&D laboratory and equipment Scientists with deep expertise in the skincare, cosmetic and pharmaceutical industries

8 Well Positioned for Growth: Product Portfolio including 250+ Formulations Non-Prescription Prescription MiCal 1 MiCal 2

9 Well Positioned for Growth: Combining our Products and Technologies Combining our products and knowhow to fuel growth: MiCal 1 MiCal 2 Innovation Line Extensions New Product launches

10 Well Positioned for Growth: Sales & Manufacturing Infrastructure in Canada 50,000 sqft plant in Laval, QC, Canada Modern, Health Canada-compliant GMP facility Available production capacity 73 Employees Core Competencies 250+ stable formulations; Full R&D capabilities and formulations development laboratory; Expertise and know-how in Skin Science Highly trained field force calling on medical and aesthetic spas across Canada;

11 Well Positioned for Growth: Highly Committed & Passionate Executive Team

12 Key Management Accomplishments to Date Completed Pliaglis out-licensing agreement with Taro Completed acquisition of the Alyria line of products New President Serge Verreault Freed up $6.0 million of cash to fund working capital through amendment of loan Agreement with Knight Therapeutics Inc. Completed $1.0 million financing with Bloom Burton 12

13 Milestone Opportunities Geared for Growth Pliaglis relaunch in U.S. market by Taro Pliaglis launch in Canada MiCal 1 Potential out-licensing upfront payment FDA Approval of Not for Home Use label restriction removal Significant milestones and royalties potential from Pliaglis continue Significant milestones and royalties potential from relaunch of Pliaglis in U.S. Milestone U.S. regulatory approval of Flexicaine *Timing of events reflects management s best estimate based on currently available information. Many factors may affect the realization and timing of such events which may not be as presented above. 13

14 Revenue Generating Potential* *This does not represent forward-looking information. 14

15 Financial Snapshot (in CAD) Stock Symbol Market Cap (as at January 25) Shares Outstanding* Fully Diluted Shares Outstanding* $9.0 million $0.64 share price 14.0 million 16.7 million Share Price 52-week Low-High $ $1.47 Cash and Cash Equivalents* Long-Term Debt (Current and Long-Term portions)* $8.8 million $4.3 million * Cash and Cash Equivalents, Long-term Debt and the number of shares outstanding and fully diluted shares outstanding figures are as at September 30,

16 Our Strengths Our commercial products and infrastructure complement our capabilities in R&D and topical product development. Crescita features: Strong niche brands catering to spas and medispas Superior formulations with clinically proven results Diversified portfolio providing full skincare solutions Innovative technologies Fully integrated sales and marketing infrastructure Health Canada GMP Compliant Plant Passionate and committed Management and staff 16

17 Summary of Investment Highlights Crescita represents an excellent investment opportunity: Undervalued and trading near cash value Prescription products, led by Pliaglis in the U.S., represent significant upside potential Non-prescription business well positioned for domestic and international growth Numerous strategic tuck-in acquisitions and international distributorships being pursued CMO business is growing 17